OCUL — Ocular Therapeutix Income Statement
0.000.00%
Last trade - 00:00
- $1.22bn
- $799.45m
- $58.44m
- 54
- 15
- 88
- 51
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 4.23 | 17.4 | 43.5 | 51.5 | 58.4 |
Cost of Revenue | |||||
Gross Profit | 1.9 | 15.3 | 39.1 | 47 | 53.2 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 90 | 80.3 | 122 | 130 | 127 |
Operating Profit | -85.8 | -62.8 | -78 | -78.7 | -68.2 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -86.4 | -156 | -6.55 | -71 | -80.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | -86.4 | -156 | -6.55 | -71 | -80.7 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -86.4 | -156 | -6.55 | -71 | -80.7 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -86.4 | -156 | -6.55 | -71 | -80.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.91 | -2.56 | -0.086 | -0.924 | -1.19 |